Boston Scientific is scrapping its $230 million plan to buy a majority stake in M.I. Tech, a Korean company that builds surgical tools, the company confirmed to STAT. Instead, it will purchase a minority stake of around 10%. That purchase will go through later this year.
“Our agreement to purchase the majority stake of M.I.Tech Co., Ltd, from Synergy Innovation Co., Ltd, required global regulatory approvals that we were not able to obtain in some countries,” said Boston Scientific spokesperson Kate Haranis. “While we are disappointed that we will not complete this purchase as initially constructed, we are committed to investing in innovative, patient-centric technologies that solve unmet clinical needs and to continuing to grow our relationship with M.I.Tech.”
The Federal Trade Commission took credit for cracking down on the deal on Wednesday.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect